Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.
Saved in:
| Title: | Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. |
|---|---|
| Authors: | Silvestris N; IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy. Electronic address: n.silvestris@oncologico.bari.it., Argentiero A; IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, Italy., Beretta GD; Medical Oncology Department, Humanitas Gavazzeni, Bergamo, Italy., Di Bartolo P; Diabetology Unit, Rete Clinica di Diabetologia Aziendale - Dipartimento, Internistico di Ravenna - AUSL Romagna, Ravenna, Italy., Montagnani M; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy., Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy., Ferrari P; Palliative Care Unit, Istituti Clinici Scientifici Maugeri SPA SB, IRCCS (PV), Italy., D'Oronzo S; IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy., Gori S; Oncologia Medica, IRCCS Ospedale Don Calabria-Sacro Cuore di Negrar, Verona, Italy., Russo A; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy., Acquati S; Endocrinology Unit, Ospedale Pierantoni-Morgagni, Forlì, Italy., Gallo M; Oncological Endocrinology Unit, Department of Medical Sciences, University of Torino, AOU Città della Salute e della Scienza di Torino, Torino, Italy. |
| Source: | Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2020 Oct; Vol. 154, pp. 103066. Date of Electronic Publication: 2020 Aug 15. |
| Publication Type: | Journal Article; Review; Consensus Statement |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 32853883 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Silvestris+N%22">Silvestris N</searchLink>; IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy. Electronic address: n.silvestris@oncologico.bari.it.<br /><searchLink fieldCode="AU" term="%22Argentiero+A%22">Argentiero A</searchLink>; IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, Italy.<br /><searchLink fieldCode="AU" term="%22Beretta+GD%22">Beretta GD</searchLink>; Medical Oncology Department, Humanitas Gavazzeni, Bergamo, Italy.<br /><searchLink fieldCode="AU" term="%22Di+Bartolo+P%22">Di Bartolo P</searchLink>; Diabetology Unit, Rete Clinica di Diabetologia Aziendale - Dipartimento, Internistico di Ravenna - AUSL Romagna, Ravenna, Italy.<br /><searchLink fieldCode="AU" term="%22Montagnani+M%22">Montagnani M</searchLink>; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy.<br /><searchLink fieldCode="AU" term="%22Danesi+R%22">Danesi R</searchLink>; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Ferrari+P%22">Ferrari P</searchLink>; Palliative Care Unit, Istituti Clinici Scientifici Maugeri SPA SB, IRCCS (PV), Italy.<br /><searchLink fieldCode="AU" term="%22D'Oronzo+S%22">D'Oronzo S</searchLink>; IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy.<br /><searchLink fieldCode="AU" term="%22Gori+S%22">Gori S</searchLink>; Oncologia Medica, IRCCS Ospedale Don Calabria-Sacro Cuore di Negrar, Verona, Italy.<br /><searchLink fieldCode="AU" term="%22Russo+A%22">Russo A</searchLink>; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.<br /><searchLink fieldCode="AU" term="%22Acquati+S%22">Acquati S</searchLink>; Endocrinology Unit, Ospedale Pierantoni-Morgagni, Forlì, Italy.<br /><searchLink fieldCode="AU" term="%22Gallo+M%22">Gallo M</searchLink>; Oncological Endocrinology Unit, Department of Medical Sciences, University of Torino, AOU Città della Salute e della Scienza di Torino, Torino, Italy. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228916049%22">Critical reviews in oncology/hematology</searchLink> [Crit Rev Oncol Hematol] 2020 Oct; Vol. 154, pp. 103066. <i>Date of Electronic Publication: </i>2020 Aug 15. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review; Consensus Statement – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Scientific+Publishers%22">Elsevier Scientific Publishers </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8916049 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0461 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210408428%22">10408428 </searchLink><i>NLM ISO Abbreviation: </i>Crit Rev Oncol Hematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32853883 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.critrevonc.2020.103066 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 103066 Titles: – TitleFull: Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Silvestris N – PersonEntity: Name: NameFull: Argentiero A – PersonEntity: Name: NameFull: Beretta GD – PersonEntity: Name: NameFull: Di Bartolo P – PersonEntity: Name: NameFull: Montagnani M – PersonEntity: Name: NameFull: Danesi R – PersonEntity: Name: NameFull: Ferrari P – PersonEntity: Name: NameFull: D'Oronzo S – PersonEntity: Name: NameFull: Gori S – PersonEntity: Name: NameFull: Russo A – PersonEntity: Name: NameFull: Acquati S – PersonEntity: Name: NameFull: Gallo M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2020 Oct Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1879-0461 Numbering: – Type: volume Value: 154 Titles: – TitleFull: Critical reviews in oncology/hematology Type: main |
| ResultId | 1 |
